ACME Laboratories (DHA:ACMELAB) ROCE %: 16.68% (As of Mar. 2026)


DHA:ACMELAB ACME Laboratories Ltd DHA:ACMELAB
82 GF Score
Price BDT81.30
GF Value BDT124.74
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is ACME Laboratories ROCE %?

ACME Laboratories DHA:ACMELAB +0.37% 82 ROCE % is 16.68% as of Mar. 2026. GuruFocus rates DHA:ACMELAB with a GF Score™ of 82/100 and a GF Value™ of BDT124.74 (Possible Value Trap). The stock has 7 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ACME Laboratories's annualized ROCE % for the quarter that ended in Mar. 2026 was 16.68%.

ACME Laboratories  (DHA:ACMELAB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ACME Laboratories ROCE % Related Terms

ACME Laboratories ROCE % Historical Data

* Premium members only.

The historical data trend for ACME Laboratories's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACME Laboratories ROCE % Chart

ACME Laboratories Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
ROCE %
Get a 7-Day Free Trial Premium Member Only 15.52 13.98 14.64 14.69 16.78

ACME Laboratories Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.33 19.94 18.81 18.66 16.68
DHA:ACMELAB
82GF Score
ACME Laboratories Ltd DHA:ACMELAB
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACME Laboratories ROCE % Calculation

ACME Laboratories's annualized ROCE % for the fiscal year that ended in Jun. 2024 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2024 )  (A: Jun. 2023 )(A: Jun. 2024 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2024 )  (A: Jun. 2023 )(A: Jun. 2024 )
=5501.04/( ( (50410.022 - 18953.412) + (55622.164 - 21530.922) )/ 2 )
=5501.04/( (31456.61+34091.242)/ 2 )
=5501.04/32773.926
=16.78 %

ACME Laboratories's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=6236.384/( ( (60115.544 - 22998.137) + (59535.015 - 21886.899) )/ 2 )
=6236.384/( ( 37117.407 + 37648.116 )/ 2 )
=6236.384/37382.7615
=16.68 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 16.68% mean?
ACME Laboratories (DHA:ACMELAB) has a ROCE % of 16.68% as of Mar. 2026.
Is ACME Laboratories' ROCE % too high?
ACME Laboratories' current ROCE % is 16.68%. The Drug Manufacturers industry median ROCE % is 7.00. ACME Laboratories' value of 16.68% is 138.5% above this industry median. Overall, ACME Laboratories has a GF Score™ of 82/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ACME Laboratories' ROCE % compare to ZTS and UTHR?
ACME Laboratories' ROCE % of 16.68% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. ACME Laboratories' value of 16.68% is 138.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACME Laboratories's current ROCE % of 16.68% is 138.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACME Laboratories's current ROCE % is 16.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACME Laboratories stock overvalued right now?
Based on GuruFocus' analysis, ACME Laboratories (DHA:ACMELAB) is currently considered Possible Value Trap. The stock's GF Value™ is BDT124.74, compared to a current price of BDT81.30 — trading 34.8% below its estimated fair value. The current ROCE % is 16.68% and 138.5% above the Drug Manufacturers industry median of 7.00. ACME Laboratories' overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For ACME Laboratories (DHA:ACMELAB), the current ROCE % is 16.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACME Laboratories (DHA:ACMELAB) Overvalued in 2026?

Based on GuruFocus' analysis, ACME Laboratories stock appears to be undervalued. The current stock price of BDT81.30 is trading 34.8% below its estimated GF Value™ of BDT124.74. GuruFocus considers ACME Laboratories to be Possible Value Trap.

Key valuation signals for DHA:ACMELAB:

  • ROCE %: 16.68%
  • GF Value™: BDT124.74 vs. price of BDT81.30 (34.8% below fair value)
  • GF Score™: 82/100 with 7 warning signs
  • Industry Position: 138.5% above the Drug Manufacturers median

No single metric tells the full story. See the DHA:ACMELAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACME Laboratories Business Description

Address 1/4, Kallayanpur, Mirpur Road, Court de la ACME, Dhaka, BGD, 1207
ACME Laboratories Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products in Bangladesh. The Company is engaged in manufacturing, marketing, and distribution of generic pharmaceuticals formulation products which includes human drugs comprising dosages form like a tablet, capsule, dry syrup, cream, ointment, powder, injection, dry powder inhaler, metered dosage inhaler, suppository, eye and nasal drop, liquid, liquid in hard gelatine, Blow Fill Seal (BFS) products, sachet products; veterinary drugs comprising dosages form like bolus, liquid,injection, water-soluble powder, premix and herbal drugs comprising dosages form like liquid, capsule, tablet, cream. The products of the company are sold in domestic and international markets.
82GF Score

Get the complete analysis for DHA:ACMELAB

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT81.30
Price
BDT124.74
GF Value